Immunogenicity and protective efficacy of influenza vaccination

Hannoun, C.; Megas, Françoise; Piercy, James

doi:10.1016/j.virusres.2004.02.025

Cited by 242 publications

(172 citation statements)

References 44 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…This improvement in thymic output could be translated into an enhanced in vivo response to influenza virus, a virus that causes considerable morbidity and mortality in the elderly (29). This was demonstrated by a lower viral load in fusionand IL-7-treated animals, which agrees with previous data reporting a lower viral burden during infection with influenza (30) and HSV type-1 (31) following treatment with rIL-7.…”

Section: Discussionsupporting

confidence: 88%

An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability

Henson

Snelgrove

Hussell

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output. Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

show abstract

Section: Discussionsupporting

confidence: 88%

An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability

Henson

Snelgrove

Hussell

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Antibody responses were detected by means of hemagglutination inhibition (HI) assays, according to established procedures and with use of turkey erythrocytes (9,10), at the Korea University Guro Hospital. Titers of antihemagglutinin (anti-HA) antibodies that were below the detection limit (i.e., Ͻ1:10) were assigned a value of 1:5, and titers above 1:5,120 were assigned a value of 1:5,120.…”

Section: Methodsmentioning

confidence: 99%

Long-Term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine among Health Care Workers: Influence of Prior Seasonal Influenza Vaccination

Song

Cheong

Seo

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

dHealth care workers (HCWs) are at great risk of influenza infection and transmission. Vaccination for seasonal influenza is routinely recommended, but this strategy should be reconsidered in a pandemic situation. Between October 2009 and September 2010, a multicenter study was conducted to assess the long-term immunogenicity of the A/H1N1 2009 monovalent influenza vaccine among HCWs compared to non-health care workers (NHCWs). The influence of prior seasonal influenza vaccination was also assessed with respect to the immunogenicity of pandemic H1N1 influenza vaccine. Serum hemagglutinin inhibition titers were determined prevaccination and then at 1, 6, and 10 months after vaccination. Of the 360 enrolled HCW subjects, 289 participated in the study up to 10 months after H1N1 monovalent influenza vaccination, while 60 of 65 NHCW subjects were followed up. Seroprotection rates, seroconversion rates, and geometric mean titer (GMT) ratios fulfilled the European Union's licensure criteria for influenza A/California/7/2009 (H1N1) at 1 month after vaccination in both the HCWs and NHCWs, without any significant difference. At 6 months after vaccination, the seroprotection rate was more significantly lowered among the NHCWs than among the HCWs (P < 0.01). Overall, postvaccination (1, 6, and 10 months after vaccination) GMTs for A/California/7/ 2009 (H1N1) were significantly lower among the seasonal influenza vaccine recipients than among the nonrecipients (P < 0.05). In conclusion, HCWs should be encouraged to receive an annual influenza vaccination, considering the risk of repeated exposure. However, prior reception of seasonal influenza vaccine showed a negative influence on immunogenicity for the pandemic A/H1N1 2009 influenza vaccine.

show abstract

“…Sampling for immunogenicity assays was performed before the first dose (day 0), 21 days after the first vaccination (day 21), and 21 days after the second vaccination (day 42). Antibody responses were detected by hemagglutination inhibition (HI) assays according to established procedures and using turkey erythrocytes (10,12) at the Korea University Guro Hospital. Titers of antihemagglutinin antigen antibodies that were below the detection limit (i.e., Ͻ1:10) were assigned a value of 1:5, and titers above 1:5,120 were assigned a value of 1:5,120.…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity and Safety of the Influenza A/H1N1 2009 Inactivated Split-Virus Vaccine in Young and Older Adults: MF59-Adjuvanted Vaccine versus Nonadjuvanted Vaccine

Cheong

Song

Heo

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

Since initial reports in April 2009, the pandemic influenza A (H1N1) virus has spread globally. Influenza vaccines are the primary method for the control of influenza and its complications. We conducted a multicenter clinical trial to evaluate the immunogenicity and safety of H1N1 vaccine (Green Cross Co.) in young adults (18 to 64 years) and the elderly (>65 years) using a two-dose regimen, with the doses administered 21 days apart. Three different regimens of hemagglutinin antigen were comparatively analyzed: 3.75 g (MF59 adjuvanted) versus 7.5 g (MF59 adjuvanted) versus 15 g (nonadjuvanted) in young adults and 3.75 g (MF59 adjuvanted) versus 7.5 g (MF59 adjuvanted) in the elderly. In young adults, all three vaccine regimens met the European Agency for the Evaluation of Medicinal Products (EMA) criteria after the first dose. In the elderly, on day 21 after the first dose, the rates of seroprotection and seroconversion were significantly higher for the 7.5-g dose of MF59 adjuvanted vaccine than for the 3.75-g dose (58.0% versus 44.3% [P ‫؍‬ 0.03] and 53.7% versus 37.2% [P < 0.01], respectively). After the second dose, the geometric mean titer (GMT) increment was blunted with a 15-g dose of nonadjuvanted vaccine, whereas the GMT increased about 2-fold with MF59 adjuvanted vaccines. In conclusion, a single 7.5-g dose of MF59 adjuvanted vaccine would have a practical advantage over a two-dose, 3.75-g, MF59 adjuvanted vaccine priming schedule. Following a two-dose priming schedule, the increase in hemagglutinin inhibition titers was higher with MF59 adjuvanted vaccine than with nonadjuvanted vaccine.

show abstract

Immunogenicity and protective efficacy of influenza vaccination

Cited by 242 publications

References 44 publications

An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability

An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability

Long-Term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine among Health Care Workers: Influence of Prior Seasonal Influenza Vaccination

Immunogenicity and Safety of the Influenza A/H1N1 2009 Inactivated Split-Virus Vaccine in Young and Older Adults: MF59-Adjuvanted Vaccine versus Nonadjuvanted Vaccine

Contact Info

Product

Resources

About